Gastric cancer(GC)remains one of the most common cancers and serious health problems worldwide.For unresectable or metastatic advanced gastric cancer,chemotherapy treatment is first selected.Although chemotherapy has ...Gastric cancer(GC)remains one of the most common cancers and serious health problems worldwide.For unresectable or metastatic advanced gastric cancer,chemotherapy treatment is first selected.Although chemotherapy has improved survival in patients with advanced gastric cancer(AGC),the prognosis of these patients remains poor.In recent years,some therapies targeting biological molecules have been reported to prolong the survival of patients with AGC.Since trastuzumab,a monoclonal antibody that targets HER2,was established as standard therapy for unresectable GC in a HER2-positive patient,many other targets have been reported as new therapy targets.Many molecular targeted therapies,such as HER2,VEGFR or EGFR,have been verified as established standard treatments with or without chemotherapy in clinical trials.Furthermore,immunotherapy is expected to be an effective treatment with promising clinical trial data.Especially,immune checkpoint inhibiters,such as PD-1/PD-L1 or CTLA-4,have demonstrated innovative progression in GC therapy.Moreover,ongoing clinical trials including targeted therapy and immunotherapy have shown promising results in improving clinical outcomes,safety,and tolerability.In this article,we review targeting therapies and immunotherapies for GC and summarize future prospective treatments.展开更多
文摘Gastric cancer(GC)remains one of the most common cancers and serious health problems worldwide.For unresectable or metastatic advanced gastric cancer,chemotherapy treatment is first selected.Although chemotherapy has improved survival in patients with advanced gastric cancer(AGC),the prognosis of these patients remains poor.In recent years,some therapies targeting biological molecules have been reported to prolong the survival of patients with AGC.Since trastuzumab,a monoclonal antibody that targets HER2,was established as standard therapy for unresectable GC in a HER2-positive patient,many other targets have been reported as new therapy targets.Many molecular targeted therapies,such as HER2,VEGFR or EGFR,have been verified as established standard treatments with or without chemotherapy in clinical trials.Furthermore,immunotherapy is expected to be an effective treatment with promising clinical trial data.Especially,immune checkpoint inhibiters,such as PD-1/PD-L1 or CTLA-4,have demonstrated innovative progression in GC therapy.Moreover,ongoing clinical trials including targeted therapy and immunotherapy have shown promising results in improving clinical outcomes,safety,and tolerability.In this article,we review targeting therapies and immunotherapies for GC and summarize future prospective treatments.
